Ghauri Aymen Owais, Mohiuddin Ejaz, Rehman Tayyeba, Siddiqui Hk Sheraz Muhammad
Aymen Owais Ghauri, PhD Eastern Medicine (fellow) Department of Eastern Medicine, Jinnah University for Women, Karachi, 74600, Pakistan. Faculty of Eastern Medicine, Hamdard University, Karachi, Pakistan.
Dr. Ejaz Mohiuddin, MBBS PhD Eastern Medicine Faculty of Eastern Medicine, Hamdard University, Karachi, Pakistan.
Pak J Med Sci. 2022 Jul-Aug;38(6):1668-1673. doi: 10.12669/pjms.38.6.5928.
PHF-dia (Poly Herbal Formulation Diabetes) is a polyhedral formulation possessing antihyperglycemic and antihyperlipdimic effects. This study aims to assess acute and sub-acute toxicity of PHF-dia in rats.
This is an experimental study conducted in two different phases. Acute toxicity was conducted for 14 days and sub-acute toxicity was conducted for 28 days. Both studies were conducted in animal house of Jinnah University for Women, Karachi, Pakistan. Acute toxicity was evaluated in vivo with single time oral administration of 400 mg/kg and 2000 mg/kg doses for two weeks. Sub-acute toxicity was investigated with the application of repeated doses of 150 mg/kg/day, 250 mg/kg/day and 500 mg/kg/day for 28 days.
Acute toxicity study results showed no toxic symptoms, behavioral changes or death in rats up to 2000 mg/kg. Therefore, LD of oral toxic dose must be more than 2000 mg/ml. Similarly, sub-acute toxicity studies confirmed the safety of PHF-dia and showed no clinical symptoms nor biochemical or histological variation in rats treated with 150 mg/kg, 250 mg/kg and 500 mg/kg compared to the control group (p <0.05).
This indicates safe nature of PHF-dia for the further clinical trials. However, mechanism of action of PHF-dia is not fully understood.
PHF-dia(复方草药糖尿病制剂)是一种具有降血糖和降血脂作用的多面体制剂。本研究旨在评估PHF-dia对大鼠的急性和亚急性毒性。
这是一项分两个不同阶段进行的实验研究。急性毒性实验持续14天,亚急性毒性实验持续28天。两项研究均在巴基斯坦卡拉奇真纳女子大学动物房进行。急性毒性通过单次口服400 mg/kg和2000 mg/kg剂量进行为期两周的体内评估。亚急性毒性通过给予150 mg/kg/天、250 mg/kg/天和500 mg/kg/天的重复剂量进行28天的研究。
急性毒性研究结果显示,高达2000 mg/kg剂量时大鼠未出现毒性症状、行为变化或死亡。因此,口服毒性剂量的半数致死量必须大于2000 mg/ml。同样,亚急性毒性研究证实了PHF-dia的安全性,与对照组相比,接受150 mg/kg、250 mg/kg和500 mg/kg治疗的大鼠未出现临床症状,生化或组织学也无变化(p<0.05)。
这表明PHF-dia用于进一步临床试验具有安全性。然而,PHF-dia的作用机制尚未完全明确。